TLPH - Talphera Inc.

TLPH - Talphera Inc.

https://talphera.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Talphera Cuts Expenses 14 Percent

Motley Fool • 1 month ago • score: 0.10

Talphera ( NASDAQ:TLPH ) , a specialty pharmaceutical company developing therapies for medically supervised hospital settings, reported its second quarter 2025 results on August 14, 2025. The company posted an EPS loss of $0.10 ( GAAP ) , which was better than the analyst consensus estimate of a ...

All You Need to Know About Talphera ( TLPH ) Rating Upgrade to Strong Buy

Zacks Commentary • 4 months, 1 week ago • score: 0.40

Talphera (TLPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Talphera ( TLPH ) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Commentary • 5 months, 1 week ago • score: 0.36

Talphera (TLPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update

PR Newswire • 1 year, 6 months ago • score: 0.18

Company rebranding and corporate transformation to Talphera completed in Q1 2024 First patient enrollment in the NEPHRO CRRT registrational study expected in Q1 2024 with a projected PMA submission by the end of 2024

Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members

PR Newswire • 1 year, 6 months ago • score: 0.36

SAN MATEO, Calif., March 1, 2024 /PRNewswire/ -- Talphera, Inc. ( Nasdaq: TLPH ) , ( Talphera ) , a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced as part of its commitment to ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

None

52W High

$1.19

52W Low

$0.38

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-0.17

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.11

EV/Revenue (<3 favorable)

165.93

P/S (TTM) (<3 favorable)

417.45

P/B (<3 favorable)

1.70

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

2.64%

Institutions (25–75% balanced)

30.10%

Shares Outstanding

20,522,700

Float

18,046,200

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

27,000

Gross Profit (TTM)

-6,018,000

EPS (TTM)

-0.39

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-494.59%

ROE (TTM) (>15% strong)

-1.18%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.1455

Previous

0.1327

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025